Zacks Investment Research lowered shares of Eisai Co., Ltd (NASDAQ:ESALY) from a hold rating to a sell rating in a research report sent to investors on Friday morning.
According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “
Eisai Co. (NASDAQ:ESALY) opened at 55.315 on Friday. The firm has a 50-day moving average price of $52.91 and a 200 day moving average price of $53.17. The stock has a market capitalization of $15.83 billion and a PE ratio of 58.288. Eisai Co. has a 12 month low of $50.31 and a 12 month high of $65.76.
TRADEMARK VIOLATION WARNING: “Zacks Investment Research Downgrades Eisai Co., Ltd (ESALY) to Sell” was originally published by BBNS and is the property of of BBNS. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/zacks-investment-research-downgrades-eisai-co-ltd-esaly-to-sell/1739796.html.
Eisai Co. Company Profile
Eisai Co, Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company’s businesses include pharmaceutical business and other business. The Company’s segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South America), China, Asia (South Korea, Taiwan, Hong Kong, India and ASEAN), EMEA (Europe, the Middle East, Africa and Oceania) and Consumer Healthcare Business-Japan.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eisai Co. Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai Co. Ltd and related companies with our FREE daily email newsletter.